Human antibodies that bind human TNF.alpha.

US6258562A · kind A · utility

Assignee

• BASF SE

Inventors

• Jochen G. Salfeld · North Grafton, US
• Deborah J. Allen · London, GB
• Hendricus R. J. M. Hoogenboom · Eijsden, NL
• Zehra Kaymakcalan · Westborough, US
• Boris Labkovsky · Framingham, US
• John A. Mankovich · Andover, US
• Brian McGuinness · Cambridge, GB
• Andrew J. Roberts · Cambridge, GB
• Paul Sakorafas · Newton, US
• David Schoenhaut · Clifton, US
• Tristan Vaughan · Cambridge, GB
• Michael White · Framingham, US
• Alison J. Wilton · Cambridge, GB

Key dates

• Filing date: Mar 16, 1999
• Grant date: Jul 10, 2001
• Expiry date: Mar 16, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S424/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha.(hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.off =10.sup.-3 sec.sup.-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.